Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/02656736.2018.1548034
- Scopus: eid_2-s2.0-85058716633
- PMID: 30556448
- WOS: WOS:000463828700001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: High intensity focused ultrasound (HIFU) ablation of benign thyroid nodule is safe and efficacious in patients who continue taking an anti-coagulation or anti-platelet agent in the treatment period
Title | High intensity focused ultrasound (HIFU) ablation of benign thyroid nodule is safe and efficacious in patients who continue taking an anti-coagulation or anti-platelet agent in the treatment period |
---|---|
Authors | |
Keywords | Anticoagulants Hemorrhage High-intensity focused ultrasound ablation Platelet aggregation inhibitors Thyroid nodule |
Issue Date | 2019 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/02656736.asp |
Citation | International Journal of Hyperthermia, 2019, v. 36 n. 1, p. 186-190 How to Cite? |
Abstract | Background: High intensity focused ultrasound (HIFU) ablation is a promising treatment for benign thyroid nodules but because bleeding complications can occur following any intervention to the thyroid gland, the safety and efficacy of HIFU ablation were evaluated in patients who continued taking an anti-coagulation or anti-platelet agent during treatment.
Methods: From 2015 to 2017, 303 patients who underwent a single-session ablation for a benign thyroid nodule were analyzed. The primary study endpoint was thyroid bleeding, intra-lesional or peri-thyroidal hematoma or neck bruising diagnosed within 4 days of the treatment. Other endpoints included treatment-related complications, extent of nodule shrinkage and symptom score. Nodule volume was estimated by ultrasound. Extent of nodule shrinkage (by volume reduction ratio) (VRR)= [Baseline volume – volume at 6-month]/[Baseline volume] × 100. Obstructive symptom score (by 0– 10 visual analog scale, VAS) was evaluated after treatment.
Results: Twelve patients continued taking an anti-coagulation or anti-platelet agent while the other 291 patients did not during treatment. No patients in either group suffered active thyroid bleeding, intralesional/pericapsular hematoma or subcutaneous neck bruising in the first 4 days of treatment. Complication rate and the 6-month VRR were comparable between the two groups (0.0% vs. 1.7%, p = 1.000 and 55.96% vs. 61.29%, respectively, p = .073).
Conclusions: HIFU ablation is a feasible treatment in patients who continue to take an anti-coagulation or anti-platelet agent during treatment and might be preferable in patients who continuously require an anti-coagulation or anti-platelet agent for one reason or another during treatment. |
Persistent Identifier | http://hdl.handle.net/10722/266428 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 0.827 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lang, HHB | - |
dc.contributor.author | Woo, YC | - |
dc.contributor.author | Chiu, WHK | - |
dc.date.accessioned | 2019-01-18T08:19:25Z | - |
dc.date.available | 2019-01-18T08:19:25Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | International Journal of Hyperthermia, 2019, v. 36 n. 1, p. 186-190 | - |
dc.identifier.issn | 0265-6736 | - |
dc.identifier.uri | http://hdl.handle.net/10722/266428 | - |
dc.description.abstract | Background: High intensity focused ultrasound (HIFU) ablation is a promising treatment for benign thyroid nodules but because bleeding complications can occur following any intervention to the thyroid gland, the safety and efficacy of HIFU ablation were evaluated in patients who continued taking an anti-coagulation or anti-platelet agent during treatment. Methods: From 2015 to 2017, 303 patients who underwent a single-session ablation for a benign thyroid nodule were analyzed. The primary study endpoint was thyroid bleeding, intra-lesional or peri-thyroidal hematoma or neck bruising diagnosed within 4 days of the treatment. Other endpoints included treatment-related complications, extent of nodule shrinkage and symptom score. Nodule volume was estimated by ultrasound. Extent of nodule shrinkage (by volume reduction ratio) (VRR)= [Baseline volume – volume at 6-month]/[Baseline volume] × 100. Obstructive symptom score (by 0– 10 visual analog scale, VAS) was evaluated after treatment. Results: Twelve patients continued taking an anti-coagulation or anti-platelet agent while the other 291 patients did not during treatment. No patients in either group suffered active thyroid bleeding, intralesional/pericapsular hematoma or subcutaneous neck bruising in the first 4 days of treatment. Complication rate and the 6-month VRR were comparable between the two groups (0.0% vs. 1.7%, p = 1.000 and 55.96% vs. 61.29%, respectively, p = .073). Conclusions: HIFU ablation is a feasible treatment in patients who continue to take an anti-coagulation or anti-platelet agent during treatment and might be preferable in patients who continuously require an anti-coagulation or anti-platelet agent for one reason or another during treatment. | - |
dc.language | eng | - |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/02656736.asp | - |
dc.relation.ispartof | International Journal of Hyperthermia | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Anticoagulants | - |
dc.subject | Hemorrhage | - |
dc.subject | High-intensity focused ultrasound ablation | - |
dc.subject | Platelet aggregation inhibitors | - |
dc.subject | Thyroid nodule | - |
dc.title | High intensity focused ultrasound (HIFU) ablation of benign thyroid nodule is safe and efficacious in patients who continue taking an anti-coagulation or anti-platelet agent in the treatment period | - |
dc.type | Article | - |
dc.identifier.email | Lang, HHB: Blang@hku.hk | - |
dc.identifier.email | Woo, YC: wooyucho@hku.hk | - |
dc.identifier.email | Chiu, WHK: kwhchiu@hku.hk | - |
dc.identifier.authority | Lang, HHB=rp01828 | - |
dc.identifier.authority | Chiu, WHK=rp02074 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1080/02656736.2018.1548034 | - |
dc.identifier.pmid | 30556448 | - |
dc.identifier.scopus | eid_2-s2.0-85058716633 | - |
dc.identifier.hkuros | 296555 | - |
dc.identifier.volume | 36 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 186 | - |
dc.identifier.epage | 190 | - |
dc.identifier.isi | WOS:000463828700001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0265-6736 | - |